Jeffrey Arcara - Feb 28, 2024 Form 4 Insider Report for Corvus Pharmaceuticals, Inc. (CRVS)

Role
Chief Business Officer
Signature
/s/ Leiv Lea, as Attorney-in-Fact for Jeffrey Arcara
Stock symbol
CRVS
Transactions as of
Feb 28, 2024
Transactions value $
$0
Form type
4
Date filed
3/1/2024, 05:57 PM
Previous filing
Feb 8, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRVS Stock Option (Right to Buy) Award $0 +400K $0.00 400K Feb 28, 2024 Common Stock 400K $2.30 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The underlying shares subject to the option vest and become exercisable as to 1/36th of the shares subject to the option in successive, equal monthly installments measured from February 2, 2024, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.